

<b>Statistical analysis title</b>	Cohort 1, ACP: Fesoterodine 4 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per catheterisation and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 4 mg
Number of subjects included in analysis	36
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0610
Method	ANCOVA
Confidence interval	
<b>Statistical analysis title</b>	Cohort 1, ACP: Fesoterodine 8 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per catheterisation and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 8 mg

Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0048
Method	ANCOVA
Confidence interval	
<b>Statistical analysis title</b>	Cohort 1, ACP: Oxybutynin
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per catheterisation and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Oxybutynin
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0100

Method	ANCOVA
Confidence interval	